



medicines
patent
pool

Meds PaL

THE MEDICINES PATENTS AND LICENCES DATABASE

www.medspal.org

THE MEDICINES PATENT POOL


Created in 2010 as first voluntary licensing and patent pooling mechanism in public health

To increase access to new treatments for HIV through licensing of patented medicines

And facilitate innovation
e.g. new fixed dose combinations and paediatric formulations


In 2015, expanded mandate to **Hepatitis C** and **Tuberculosis**

In 2018, decision to expand to **other patented essential medicines**



MPP's activities in HIV, HCV and TB are funded by:

WHY DID WE START COLLECTING PATENT DATA?



- In order to prioritize medicines for in-licensing, the MPP set out to **collect patent status data** on HIV medicines from LMICs
- Through national patent searches and the **support of WIPO and many patent offices** the MPP managed to obtain information for a large number of LMICs
- Many **requests for data** from public health stakeholders convinced MPP to **make data public**

April 2011: launch of the MPP Patent Status Database, an enhanced worksheet including 24 HIV medicines in 88 countries



The screenshot shows the MPP Patent Status Database interface. It features a search bar at the top left with the MPP logo. Below the search bar is a table with multiple columns and rows, displaying patent information for various medicines. The table includes columns for 'Medicine', 'Patent No.', 'Country', 'Status', and 'Expiry Date'. The data is organized into several rows, each representing a different medicine and its associated patent information across different countries.

MAKING PATENT DATA PUBLIC

October 2016: launch of **MedsPaL** as the most comprehensive source of information on the patent and licensing status of medicines for HIV, TB, hepatitis C and other patented essential medicines in low- and middle-income countries



INITIAL FEEDBACK FROM STAKEHOLDERS



“The Medicines Patent Pool’s Patent Status Database for Selected HIV Medicines **takes an invaluable step towards furthering access to treatment of HIV/AIDS** amassing information from numerous patent registries and jurisdictions into an easily navigable resource available to the public”

“The Medicines Patent Pool database is an **essential impartial reference source** for Global Fund Principal Recipients to understand the patent status of ARVs in their country - and it should be further expanded to include more countries.”



“In the midst of a current patent regime that is at times not so transparent, **this database is a great and valuable tool for players in the field**, and one we regularly check as part of our procedures for determining a patent status. [It] ultimately allow[s] us to focus more of our energy into the actual delivery of HIV medicines to the ones who need it.”

“The patent status database is an **incredibly useful resource** as it provides the most comprehensive pool of the available information on patent statuses, and combines this into one easy to use search engine.”





WHY DO WE NEED MEDSPAL?

**KEY QUESTION: IS MEDICINE “X”
PATENTED IN COUNTRY “Y” ?**

Example : Lopinavir

LOPINAVIR BASIC COMPOUND PATENT



US005914332A

United States Patent [19]
Sham et al.

[11] **Patent Number:** 5,914,332
[45] **Date of Patent:** Jun. 22, 1999

[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**

[75] Inventors: **Hing Leung Sham**, Mundelein; **Daniel W. Norbeck**, Crystal Lake; **Xiaoqi Chen**, Libertyville; **David A. Betebenner**, Gurnee, all of Ill.

[73] Assignee: **Abbott Laboratories**, Abbott Park, Ill.

[21] Appl. No.: **08/753,201**

[22] Filed: **Nov. 21, 1996**

Related U.S. Application Data

[63] Continuation-in-part of application No. 08/572,226, Dec. 13, 1995, abandoned.

[51] **Int. Cl.⁶** **A61K 31/415**; A61K 31/505; A61K 31/535; C07D 239/10

[52] **U.S. Cl.** **514/274**; 514/211; 514/218; 514/228.8; 514/256; 514/376; 514/377; 514/392; 540/488; 540/492; 544/88; 544/97; 544/316; 544/332; 548/229; 548/233; 548/324.1; 548/331.5

[58] **Field of Search** 548/229, 324.5, 548/233, 324.1, 331.5; 544/88, 316, 97, 332; 540/488, 492; 514/211, 218, 228.8, 274, 376, 392, 256, 377

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,142,056 8/1992 Kempf et al. 546/265
5,354,866 10/1994 Kempf et al. 546/265
5,541,206 7/1996 Kempf et al. 514/365

FOREIGN PATENT DOCUMENTS

0005689 11/1979 European Pat. Off. .

0342541 11/1989 European Pat. Off. .
365992 5/1990 European Pat. Off. .
0428849 5/1991 European Pat. Off. .
0580402 1/1994 European Pat. Off. .
8910752 11/1989 WIPO .
9307128 4/1993 WIPO .


OTHER PUBLICATIONS

Scholz, et al., J. of Med. Chem. 37 3079-3089 (1994).
Jindrich et al., Collect Czech. Chem. Commun 58 (7) 1645-1667 (1993).
Y. Becker et al., J. Org. Chem., vol. 45, (1980), pp. 2145-2151.
H. Takechi et al., Chem. Pharm. Bull., vol. 34, No. 8 (1986), pp. 3142-3152.
A. Smith et al., J. Am. Chem. Soc., vol. 117, (1995), pp. 11113-11123.
J. Vacca et al., Bioorg. Med. Chem. Lett., vol. 4, (1994), pp. 499-504.
R. Randad et al., Bioorg. Med. Chem. Lett., vol. 4, (1994), pp. 1247-1252.

Primary Examiner—Richard L. Raymond
Attorney, Agent, or Firm—Steven R. Crowley

[57] **ABSTRACT**

A compound of the formula:



is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

17 Claims, No Drawings

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) **International Patent Classification** ⁶ :
C07D 233/32, 239/10, 239/22, 207/40, 207/26, 241/08, 263/22, A61K 31/415

A1

(11) **International Publication Number:** **WO 97/21683**

(43) **International Publication Date:** 19 June 1997 (19.06.97)

(21) **International Application Number:** PCT/US96/19394

(81) **Designated States:** CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(22) **International Filing Date:** 6 December 1996 (06.12.96)

(30) **Priority Data:**
08/572,226 13 December 1995 (13.12.95) US
08/754,687 21 November 1996 (21.11.96) US

Published
With international search report.

(71) **Applicant:** ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(72) **Inventors:** SHAM, Hing, Leung; 212 Knightsbridge Drive, Mundelein, IL 60060 (US). STEWART, Kent, D.; 4715 Kings Way North, Gurnee, IL 60031 (US). KEMPF, Dale, J.; 256 Tyler, Libertyville, IL 60048 (US).

(74) **Agents:** CROWLEY, Steven, R. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(54) **Title:** RETROVIRAL PROTEASE INHIBITING COMPOUNDS

(57) **Abstract**

Inhibitors of HIV protease are provided. When bound to HIV protease, the inhibitors are characterized by a unique three-dimensional conformation and orientation relative to the S1, S1', S2, S2', S3, and S3' subsites of the protease. Pharmaceutical compositions containing the inhibitors and methods of treating HIV infection are also provided.

Priority date: 1995
Filing date: 1996

Search
“Lopinavir” in
abstract of US
granted
patents

Hits: 21
Earliest date: 2001

USPTO PATENT FULL-TEXT AND IMAGE DATABASE



Searching US Patent Collection...

Results of Search in US Patent Collection db for:

ABST/lopinavir: 21 patents.
Hits 1 through 21 out of 21

Jump To

Refine Search

PAT. NO.	Title
1 9,782,409	Treatment of cancer and benign proliferative disorders
2 9,713,622	Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
3 9,532,979	Compositions of lopinavir and ritonavir
4 9,370,578	Dosage form comprising lopinavir and ritonavir
5 9,198,912	Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
6 9,174,944	Crystalline lopinavir/surfactant adducts
7 8,895,051	Flavoring systems for pharmaceutical compositions and methods of making such compositions
8 8,796,451	Crystalline pharmaceutical
9 8,501,219	Flavoring systems for pharmaceutical compositions and methods of making such compositions
10 8,445,506	Polymorphs of lopinavir
11 8,236,991	Process for the preparation of substantially pure (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane
12 8,058,433	Crystalline pharmaceutical
13 7,906,629	Protease inhibitor conjugates and antibodies useful in immunoassay
14 7,649,085	Saquinavir conjugates and antibodies useful in immunoassay
15 7,615,542	Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV
16 7,569,678	Protease inhibitor conjugates and antibodies useful in immunoassay
17 7,482,437	Protease inhibitor conjugates and antibodies useful in immunoassay
18 7,193,065	Protease inhibitor conjugates and antibodies useful in immunoassay
19 6,911,214	Flavoring systems for pharmaceutical compositions and methods of making such compositions
20 6,864,369	Crystalline pharmaceutical
21 6,608,198	Crystalline pharmaceutical

Search
 “Lopinavir” in
 published
 applications

Hits: 4305

US PATENT & TRADEMARK OFFICE
PATENT APPLICATION FULL TEXT AND IMAGE DATABASE

- [Help](#)
- [Home](#)
- [Boolean](#)
- [Manual](#)
- [Number](#)
- [PTDLs](#)
- [Next List](#)
- [Bottom](#)
- [View Shopping Cart](#)

Searching AppFT Database...

Results of Search in AppFT Database for:
Lopinavir: 4305 applications.
 Hits 1 through 50 out of 4305


Next 50 Hits

Jump To

Refine Search

PUB. APP. NO.	Title
1	20180334732 COMPOSITIONS AND METHODS FOR HIV QUASI-SPECIES EXCISION FROM HIV-1-INFECTED PATIENTS
2	20180334430 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
3	20180333411 METHODS OF TREATMENT
4	20180333410 METHOD OF TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG
5	20180333409 METHOD OF TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG
6	20180333362 Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
7	20180333296 DRUG DELIVERY IMPLANTS AS INTRAOCULAR DRUG DEPOTS AND METHODS OF USING SAME
8	20180327834 METHODS AND SYSTEMS FOR GENETIC ANALYSIS
9	20180327725 TATk-CDKL5 Fusion Proteins, Compositions, Formulations, And Use Thereof
10	20180327411 INDOLE AHR INHIBITORS AND USES THEREOF
11	20180326018 ALKALINE PHOSPHATASE FORMULATIONS
12	20180325927 Amido-Substituted Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors
13	20180325926 Spirocyclic Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors
14	20180325889 IMMUNOREGULATORY AGENTS

Search “Lopinavir” in all searchable fields



WIPO PATENTSCOPE
Search International and National Patent Collections

Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية

WORLD INTELLECTUAL PROPERTY ORGANIZATION

Q Search | Browse | Translate | News

Home ▶ IP Services ▶ PATENTSCOPE

Results 1-10 of **2,975** for Criteria:ALL:Lopinavir Office(s):wo Language:EN Stemming: true

Page: 1 / 298 Go

Refine Search ALL:Lopinavir

Analysis

Sort by: Pub Date Asc View All List Length 10 Machine translation Side-by-side

Int.Class	Appl.No	Title	Applicant	Ctr	PubDate
A61K 9/20	PCT/EP2000/002620	1. WO/2000/059477 PREGELATINIZED STARCH IN A CONTROLLED RELEASE FORMULATION	JANSSEN PHARMACEUTICA N.V.	WO	12.10.2000
					VANDECRUYS, Roger, Petrus, Gerebern
C07D 493/04	PCT/EP2000/009917	2. WO/2001/025240 HEXAHYDROFURO'2,3-BIFURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YL SULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR	TIBOTEC PHARMACEUTICALS LTD.	WO	12.04.2001
					WIGERINCK, Piet, Tom, Bert, Paul
		3. WO/2001/044229 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS		WO	21.06.2001

The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.

The present invention relates to novel bis-tetrahydrofuran benzodioxolyl sulfonamide compounds which are surprisingly effective protease inhibitors. The invention also relates to pharmaceutical compositions, methods of inhibiting retrovirus proteases, in particular multidrug resistant retrovirus proteases, methods of treating or combating infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication.

Hits: 2975 Earliest date: 2000

Search “Lopinavir” in the field “abstract”

BRASIL Acesso à informação

Instituto Nacional da Propriedade Industrial
Ministério do Desenvolvimento, Indústria e Comércio Exterior

Consulta à Base de Dados do INPI

[Início | Ajuda?]

» Consultar por: Base Patentes | Finalizar Sessão

RESULTADO DA PESQUISA (29/11/2018 às 11:35:49)

Pesquisa por:

Resumo: 'LOPINAVIR' \

Foram encontrados **6** processos que satisfazem à pesquisa. Mostrando página **1** de **1**.

Pedido	Depósito	Título	IPC
BR 11 2015 028644 5	15/05/2014	COMPOSIÇÕES DE CENICRIVIROC E MÉTODOS DE CRIAÇÃO E USO DO MESMO	A61K 31/55
PI 1103593-5	18/07/2011	COMPOSTO HÍBRIDO DE LOPINAVIR COM RITONAVIR, PROCESSO PARA PREPARAÇÃO DO REFERIDO COMPOSTO E USO DO MESMO	C07D 277/20
PI 0714265-0	10/08/2007	COMPOSIÇÃO ORAL SÓLIDA, PROCESSO PARA PREPARAR UMA COMPOSIÇÃO ORAL SÓLIDA, USO DE UMA COMPOSIÇÃO E MÉTODO PARA TRATAR HIV	A61K 31/427
PI 0317113-2	08/12/2003	TIMINA DIOXOLANO E COMBINAÇÕES PARA USO CONTRA CEPAS RESISTENTES A 3TC/AZT DE HIV	A61K 31/70
PI 0108433-0	04/09/2001	SISTEMAS FLAVORIZANTES PARA COMPOSIÇÕES FARMACÊUTICAS E MÉTODOS PARA FAZER TAIS COMPOSIÇÕES	A61K 31/425
PI 0109433-5	21/03/2001	SUBSTÂNCIA FARMACÊUTICA CRISTALINA	C07D 239/00


Páginas de Resultados:

1

Hits: 6 - Earliest date: 2001

Search
 “Lopinavir” in
 the field
 “abstract”

Hits: 18
 Earliest date: 2002



The screenshot shows the inPASS (Indian Patent Advanced Search System) interface. At the top, there are logos for 'inPASS Indian Patent Advanced Search System' and 'INTELLECTUAL PROPERTY INDIA'. Below the logos is a navigation bar with 'Patent Search', 'Patent E-register', 'Application Status', and 'Help'. A search bar contains 'Back to search' and 'Total Document(s): 18'. The search results are displayed in a table with columns for Application Number, Title, Application Date, Status, and Application Status. The earliest date listed is 04/04/2002 for application 325/MUM/2002. The table also includes pagination controls at the bottom.

Application Number	Title	Application Date	Status	Application Status
8080/CHE/2015	NOVEL TENOFOVIR DISOPROXIL SALT AND THE PREPARATION METHOD THEREOF	31/12/2015	Published	Application Status
2216/MUM/2014	LOPINAVIR : OXALIC ACID CO-CRYSTAL AND PROCESS FOR ITS PREPARATION	04/07/2014	Published	Application Status
513/MUMNP/2014	COMPOSITIONS OF LOPINAVIR AND RITONAVIR	24/03/2014	Published	Application Status
512/MUMNP/2014	COMPOSITIONS OF LOPINAVIR	24/03/2014	Published	Application Status
2745/MUM/2013	PROCESS FOR PREPARATION OF LOPINAVIR INTERMEDIATE	22/08/2013	Published	Application Status
3338/DEL/2011	"A PHARMACEUTICAL FORMULATION IN FORM OF SURFACE STABILIZED LOPINAVIR NANOPARTICLES"	23/11/2011	Published	Application Status
2627/MUM/2011	"SOLID ANTIRETROVIRAL COMPOSITION FOR ORAL DELIVERY"	16/09/2011	Published	Application Status
665/CHE/2011	AMORPHOUS FORM OF LOPINAVIR AND RITONAVIR MIXTURE	07/03/2011	Published	Application Status
303/CHE/2011	PROCESS FOR LOPINAVIR AMORPHOUS FORM	01/02/2011	Published	Application Status
8440/DELNP/2009	"THERAPEUTIC COMPOSITIONS AND THE USE THEREOF"	23/12/2009	Published	Application Status
351/MUMNP/2009	"ANTIRETROVIRAL SOLID ORAL COMPOSITION"	16/02/2009	Published	Application Status
1744/CHE/2008	PROCESS FOR AMORPHOUS FORM OF LOPINAVIR	21/07/2008	Published	Application Status
997/CHE/2008	NOVEL CRYSTALLINE FORMS OF LOPINAVIR	22/04/2008	Published	Application Status
496/MUM/2008	NOVEL PROCESS FOR MANUFACTURE OF LOPINAVIR & RITONAVIR TABLETS	11/03/2008	Published	Application Status
894/MUMNP/2007	CRYSTALLINE PHARMACEUTICAL	14/06/2007	Published	Application Status
1184/CHE/2007	AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE (2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-HYDROXY-1,6-DIPHENYLHEXANE	08/06/2007	Published	Application Status
1269/MUM/2006	AN ANTIRETROVIRAL COMPOSITION OF LOPINAVIR AND RITONAVIR	10/08/2006	Published	Application Status
325/MUM/2002	PROCESS FOR PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIRETROVIRAL PROTEASE INHIBITOR WITH IMPROVED BIOAVAILABILITY	04/04/2002	Published	Application Status



SEARCH THE ONLINE PATENT REGISTER

Please Enter Search Criteria in The Fields Below:

Patent Number
 from: to:
 eg. 1997/06479
 use % as a wildcard
 eg. from 1997/06479
 to 1999/09480

Reference no.
 eg. 12345

Date of Application from: to:
 eg. 2004/11/28

Date of Grant from: to:
 eg. 2004/11/28

Type of Patent please select...
Patent Status please select...

Title of Invention

IPC Classification
PCT Number

Agent exactly

Applicant/Patentee exactly

Inventor exactly


HOW TO SEARCH

Please enter your search criteria in the fields provided.

Note the examples to the right of the field-boxes, and for help on each field click the field-name (in red).

For additional help, click on the following link: [search criteria](#).

https://patentsearch.cipc.co.za/patents/patentresult.aspx



[Home](#) | [Search Patents](#) | [Search Design](#) | [Contact Us](#)

[Basic Search](#)
[Advanced Search](#)

SEARCH RESULTS

Number of items returned : 0
 Title: LOPINAVIR

Current page : 0 of 0 : showing items (0 - 0)

patent no.	patent type	application date	grant date	title of invention	reference no.	patent status	ALL
1							

[search again](#)

Search
 “Lopinavir” in
 the field “Title”

Hits: 0
 Earliest date: -



US005914332A

United States Patent [19]
Sham et al.

[11] **Patent Number:** 5,914,332
[45] **Date of Patent:** Jun. 22, 1999

[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**

[75] Inventors: **Hing Leung Sham**, Mundelein; **Daniel W. Norbeck**, Crystal Lake; **Xiaoqi Chen**, Libertyville; **David A. Betebenner**, Gurnee, all of Ill.

[73] Assignee: **Abbott Laboratories**, Abbott Park, Ill.

[21] Appl. No.: **08/753,201**

[22] Filed: **Nov. 21, 1996**

Related U.S. Application Data

[63] Continuation-in-part of application No. 08/572,226, Dec. 13, 1995, abandoned.

[51] **Int. Cl.⁶** **A61K 31/415**; A61K 31/505; A61K 31/535; C07D 239/10

[52] **U.S. Cl.** **514/274**; 514/211; 514/218; 514/228.8; 514/256; 514/376; 514/377; 514/392; 540/488; 540/492; 544/88; 544/97; 544/316; 544/332; 548/229; 548/233; 548/324.1; 548/331.5

[58] **Field of Search** 548/229, 324.5, 548/233, 324.1, 331.5; 544/88, 316, 97, 332; 540/488, 492; 514/211, 218, 228.8, 274, 376, 392, 256, 377

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,142,056 8/1992 Kempf et al. 546/265
5,354,866 10/1994 Kempf et al. 546/265
5,541,206 7/1996 Kempf et al. 514/365

FOREIGN PATENT DOCUMENTS

0005689 11/1979 European Pat. Off. .

0342541 11/1989 European Pat. Off. .
365992 5/1990 European Pat. Off. .
0428849 5/1991 European Pat. Off. .
0580402 1/1994 European Pat. Off. .
8910752 11/1989 WIPO .
9307128 4/1993 WIPO .


OTHER PUBLICATIONS

Scholz, et al., J. of Med. Chem. 37 3079-3089 (1994).
Jindrich et al., Collect Czech. Chem. Commun 58 (7) 1645-1667 (1993).
Y. Becker et al., J. Org. Chem., vol. 45, (1980), pp. 2145-2151.
H. Takechi et al., Chem. Pharm. Bull., vol. 34, No. 8 (1986), pp. 3142-3152.
A. Smith et al., J. Am. Chem. Soc., vol. 117, (1995), pp. 11113-11123.
J. Vacca et al., Bioorg. Med. Chem. Lett., vol. 4, (1994), pp. 499-504.
R. Randad et al., Bioorg. Med. Chem. Lett., vol. 4, (1994), pp. 1247-1252.

Primary Examiner—Richard L. Raymond
Attorney, Agent, or Firm—Steven R. Crowley

[57] **ABSTRACT**

A compound of the formula:



is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

17 Claims, No Drawings

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) **International Patent Classification** ⁶ :
C07D 233/32, 239/10, 239/22, 207/40, 207/26, 241/08, 263/22, A61K 31/415

A1

(11) **International Publication Number:** **WO 97/21683**

(43) **International Publication Date:** 19 June 1997 (19.06.97)

(21) **International Application Number:** PCT/US96/19394

(81) **Designated States:** CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(22) **International Filing Date:** 6 December 1996 (06.12.96)

(30) **Priority Data:**
08/572,226 13 December 1995 (13.12.95) US
08/754,687 21 November 1996 (21.11.96) US

Published
With international search report.

(71) **Applicant:** ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(72) **Inventors:** SHAM, Hing, Leung; 212 Knightsbridge Drive, Mundelein, IL 60060 (US). STEWART, Kent, D.; 4715 Kings Way North, Gurnee, IL 60031 (US). KEMPF, Dale, J.; 256 Tyler, Libertyville, IL 60048 (US).

(74) **Agents:** CROWLEY, Steven, R. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(54) **Title:** RETROVIRAL PROTEASE INHIBITING COMPOUNDS

(57) **Abstract**

Inhibitors of HIV protease are provided. When bound to HIV protease, the inhibitors are characterized by a unique three-dimensional conformation and orientation relative to the S1, S1', S2, S2', S3, and S3' subsites of the protease. Pharmaceutical compositions containing the inhibitors and methods of treating HIV infection are also provided.

Priority date: 1995
Filing date: 1996



MEDSPAL CONTENT

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

www.medspal.org



Patent status data from over **110** low- and middle-income countries



Data exclusivity information from **15** countries



Covering approx. **70** medicines (over **130** formulations).



Information on all relevant licences in LMICs

Medicines for the treatment of HIV, hepatitis C and tuberculosis that are (or were) included in WHO treatment guidelines and expanded to include patented medicines on the ***WHO Essential Medicines List***
(Total: 70 medicines, over 130 formulations)

Over 210 patent families were identified and included in MedsPaL based on disclosures by patent holders to the USFDA Orange Book and Health Canada Patent Registry and supplemented with patent families disclosed in licences and in patent landscapes of reputable organizations (e.g. WHO).

MedsPaL includes patent status data on over 6,000 national patents or patent applications



PATENT SEARCHES IN MEDSPAL

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

SEARCH VIEW


MAP VIEW


Keyword Search





Products

Countries

Add/Remove Columns 

Export Patent Data 

Share This Search 

Clear Search 

Search by keywords across all fields (e.g. patent number; brand name; country, etc.)

Pre-determined search by Products (e.g. Abacavir 300mg)

Search by Countries (e.g. Chile, South Africa, Vietnam)

EXAMPLE – SEARCH RESULTS

SEARCH VIEW

MAP VIEW

?

x Bedaquiline 100 mg

x Argentina
x South Africa



Add/Remove Columns ⚙️

Export Patent Data ↓

Share This Search 🔗

Clear Search ✕

Showing result 1 out of 1 total results

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Date (dd/mm/yyyy)	Patent Application Number	Publication / Grant Number(s)	Expected Expiry Date (dd/mm/yyyy)	
	Argentina	Bedaquiline 100 mg	Bedaquiline fumarate salt	Rejected	05/12/2007	ARP070105442	AR064149A1	
			Bedaquiline to treat MDR TB	Withdrawn	27/05/2005	ARP050102200	AR049127A1	
			Bedaquiline to treat latent TB	Withdrawn	09/12/2005	ARP050105140	AR051790A1	
			Bedaquiline compounds family	Granted	24/07/2003	ARP030102655	AR040673A1	24/07/2023
	South Africa	Bedaquiline 100 mg	Bedaquiline compounds family	Granted	24/01/2005	ZA200500680	ZA200500680B	18/07/2023
			Bedaquiline to treat MDR TB	Granted	27/11/2006	ZA200609899	ZA200609899B	24/05/2025
			Bedaquiline to treat latent TB	Granted	22/06/2007	ZA200705160	ZA200705160B	08/12/2025
			Bedaquiline process	Granted	26/11/2007	ZA200710150	ZA200710150B	22/05/2026
			Bedaquiline fumarate salt	Granted	04/06/2009	ZA200903907	ZA200903907B	03/12/2027

EXAMPLE – SEARCH RESULTS

SEARCH VIEW

MAP VIEW

?
x Bedaquiline 100 mg
x Argentina
x South Africa



Add/Remove Columns ⚙️

Export Patent Data 📄

Share This Search 🔗

Clear Search ✕

Showing result 1 out of 1 total results

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Date (dd/mm/yyyy)	Patent Application Number	Publication / Grant Number(s)	Expected Expiry Date (dd/mm/yyyy)	
	Argentina	Bedaquiline 100 mg	Bedaquiline fumarate salt	Rejected	05/12/2007	ARP070105442	AR064149A1	
			Bedaquiline to treat MDR TB	Withdrawn	27/05/2005	ARP050102200	AR049127A1	
			Bedaquiline to treat latent TB	Withdrawn	09/12/2005	ARP050105140	AR051790A1	
			Bedaquiline compounds family	Granted	24/07/2003	ARP030102655	AR040673A1	24/07/2023
	South Africa	Bedaquiline 100 mg	Bedaquiline compounds family	Granted	24/01/2005	ZA200500680	ZA200500680B	18/07/2023
			Bedaquiline to treat MDR TB	Granted	27/11/2006	ZA200609899	ZA200609899B	24/05/2025
			Bedaquiline to treat latent TB	Granted	22/06/2007	ZA200705160	ZA200705160B	08/12/2025
			Bedaquiline process	Granted	26/11/2007	ZA200710150	ZA200710150B	22/05/2026
			Bedaquiline fumarate salt	Granted	04/06/2009	ZA200903907	ZA200903907B	03/12/2027

EXAMPLE – SEARCH RESULTS

SEARCH VIEW

MAP VIEW

?
x Bedaquiline 100 mg
x Argentina
x South Africa



Add/Remove Columns ⚙️

Export Patent Data 📄

Share This Search 🔗

Clear Search ✕

Showing result 1 out of 1 total results

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Date (dd/mm/yyyy)	Patent Application Number	Publication / Grant Number(s)	Expected Expiry Date (dd/mm/yyyy)	
	Argentina	Bedaquiline 100 mg	Bedaquiline fumarate salt	Rejected	05/12/2007	ARP070105442	AR064149A1	
			Bedaquiline to treat MDR TB	Withdrawn	27/05/2005	ARP050102200	AR049127A1	
			Bedaquiline to treat latent TB	Withdrawn	09/12/2005	ARP050105140	AR051790A1	
			Bedaquiline compounds family	Granted	24/07/2003	ARP030102655	AR040673A1	24/07/2023
	South Africa	Bedaquiline 100 mg	Bedaquiline compounds family	Granted	24/01/2005	ZA200500680	ZA200500680B	18/07/2023
			Bedaquiline to treat MDR TB	Granted	27/11/2006	ZA200609899	ZA200609899B	24/05/2025
			Bedaquiline to treat latent TB	Granted	22/06/2007	ZA200705160	ZA200705160B	08/12/2025
			Bedaquiline process	Granted	26/11/2007	ZA200710150	ZA200710150B	22/05/2026
			Bedaquiline fumarate salt	Granted	04/06/2009	ZA200903907	ZA200903907B	03/12/2027

Patent Card ✕

Country: South Africa

Patent Application Number: ZA200903907

Patent Status: Granted


Patent Application Date (dd/mm/yyyy): 04/06/2009

Expected Expiry Date (dd/mm/yyyy): 03/12/2027

Patent Description: Bedaquiline fumarate salt

Invention Title: Fumarate Salt Of (Alpha S,Beta R) 6 Bromo Alpha [2 (Dimethylamino)Ethyl] 2 Methoxy Alpha 1 Naphthalenyl Beta Phenyl 3 Quinolineethanol

Patent Family Identification: US FDA

Publication / Grant Number(s): [ZA200903907B](#) 

Priority Number(s): EP06125443, EP2007/063186

Patent Applicant(s): Janssen Pharmaceutica Nv

PCT Related Application(s): [WO2008068231A1](#)

Patent Status Source: National Patent Office

Last Updated (dd/mm/yyyy): 05/10/2016

[Print](#) [Copy Link](#) [Close](#)

Link, if available, to ESPACENET, the EPO database that provides patent information (in many cases including legal status) for 103 countries, including 51 LMICs.

SEARCHING FOR LOPINAVIR IN MEDSPAL

SEARCH VIEW

MAP VIEW

Keyword Search



x Lopinavir/Ritonavir 80/20 mg/ml

x India


Add/Remove Columns ⚙

Export Patent Data ↓

Share This Search 🔗

Clear Search ✕

Showing result 1 out of 1

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 India	Lopinavir/Ritonavir 80/20 mg/ml	Ritonavir crystalline polymorph	Withdrawn	IN676/MUMNP/2007	
		Ritonavir crystalline polymorph	Withdrawn	IN1638/MUMNP/2007	
		Lopinavir compound	Not Filed		
		Ritonavir compound	Not Filed		

SEARCHING FOR LOPINAVIR IN MEDSPAL

SEARCH VIEW

MAP VIEW

Keyword Search



x Lopinavir/Ritonavir 80/20 mg/ml

x India


Add/Remove Columns ⚙

Export Patent Data ↓

Share This Search 🔗

Clear Search ✕

Showing result 1 out of 1

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 India	Lopinavir/Ritonavir 80/20 mg/ml	Ritonavir crystalline polymorph	Withdrawn	IN676/MUMNP/2007	
		Ritonavir crystalline polymorph	Withdrawn	IN1638/MUMNP/2007	
		Lopinavir compound	Not Filed		
		Ritonavir compound	Not Filed		



medicines
patent
pool

LICENCE INFORMATION IN MEDSPAL

INFORMATION ON LICENCES INCLUDED

Types of Licences

Licences negotiated by the Medicines Patent Pool



Bilateral licences between originators and generics



Commitments not to enforce patents on a given product



Compulsory licences



Information in MedsPaL

Full information on the licences incl. links to summaries and full text

Information on countries, products, licensees (where public or provided by patent holder for public disclosure)

Information on countries and products

Based on publicly available information

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

SEARCH VIEW

MAP VIEW

daclatasvir



× Daclatasvir 30 mg

× India

× South Africa

Add/Remove Columns

Export Patent Data

Share This Search

Clear Search

Showing result 1 out of 1 total results

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
India	Daclatasvir 30 mg	Daclatasvir compound family	Filed	IN853/DELNP/09	09/08/2027
		Daclatasvir crystalline forms	Filed	IN806/DELNP/2010	31/07/2028
		Daclatasvir intermediate manufacturing process	Filed	IN3999/CHENP/2012	02/11/2030
		Licence(s):	MPP licence on daclatasvir (DCV)		
South Africa	Daclatasvir 30 mg	Daclatasvir compound family	Granted	ZA200900962	09/08/2027
		Daclatasvir crystalline forms	Granted	ZA201000843	31/07/2028
		Licence(s):	MPP licence on daclatasvir (DCV)		

Licence Card ✕

Title: MPP licence on daclatasvir (DCV)

Type: MPP Licence

Licensor: Bristol-Myers Squibb

Countries: Afghanistan, Algeria, Angola, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Congo, Democratic Republic of the, Cook Islands, Costa Rica, Côte d'Ivoire, Cuba, Djibouti, Dominica, Dominican Republic, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Grenada, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iraq, Jamaica, Kenya, Kiribati, Korea, DPR of, Lao PDR, Lesotho, Liberia, Libya, Madagascar, Malawi, Maldives, Mali, Marshal Islands, Mauritania, Mauritius, Micronesia, Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Philippines, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Swaziland, Syrian Arab Republic, Tanzania, United Republic of, Timor-Leste, Togo, Tonga, Tunisia, Turkmenistan, Tuvalu, Uganda, Uzbekistan, Vanuatu, Vietnam, West Bank & Gaza, Yemen, Zambia, Zimbabwe Hide last 102

Licensee(s): Aurobindo, Beximco, Cadila Healthcare, Cipla, Emcure, Hetero, Laurus Labs, Mylan, Natco Pharma, Sandoz

[Print](#) [Copy Link](#) [Close](#)

Product	Patent	Status	Application No.	Expiration Date
daclatasvir 30 mg	Daclatasvir	Granted	ZA200900962	09/09/2019
daclatasvir 30 mg	Daclatasvir compound family	Granted	ZA201000843	31/03/2020
daclatasvir 30 mg	Daclatasvir crystalline forms	Granted	ZA201000843	31/03/2020

From the licence card, users can access further information on MPP licences

This includes a summary of key features and full text of MPP licences

Links to information about other licences also included where available

DACLATASVIR (DAC)

COMPANY: BRISTOL-MYERS SQUIBB

DATE: NOVEMBER 2015



In November 2015, the MPP announced a licensing agreement with Bristol-Myers Squibb covering the direct-acting antiviral (DAA) drug, daclatasvir (DAC), and its combinations. The agreement allows generic manufacture of the hepatitis C treatment for sale in **at least 112 countries** that together are home to 65.4% of people living with HCV in low- and middle-income countries.



– LICENCE AGREEMENT



– SUBLICENCE AGREEMENT - FORM



KEY
FEATURES



PRESS
RELEASE



CHAIRMAN'S
SUMMARY



ADVISORY
GROUP
REPORT



COUNTRY
LIST



ADDITIONAL
INFORMATION

From the licence card, users can access further information on MPP licences

This includes a summary of key features and full text of MPP licences

Links to information about other licences also included where available

DACLATASVIR (DAC)

COMPANY: BRISTOL-MYERS SQUIBB

DATE: NOVEMBER 2015



In November 2015, the MPP announced a licensing agreement with Bristol-Myers Squibb covering the direct-acting antiviral (DAA) drug, daclatasvir (DAC), and its combinations. The agreement allows generic manufacture of the hepatitis C treatment for sale in **at least 112 countries** that together are home to 65.4% of people living with HCV in low- and middle-income countries.



– LICENCE AGREEMENT



– SUBLICENCE AGREEMENT - FORM



KEY
FEATURES



PRESS
RELEASE



CHAIRMAN'S
SUMMARY



ADVISORY
GROUP
REPORT



COUNTRY
LIST



ADDITIONAL
INFORMATION



medicines
patent
pool

DATA EXCLUSIVITY INFORMATION IN MEDSPAL

HOW IS INFORMATION ON DATA EXCLUSIVITY OBTAINED?

- **Data exclusivity:** Some LMICs have adopted regulations providing for data exclusivity (DE) in relation to the submission of pharmaceutical test data to regulatory authorities for approval of new medicines
- **Data on MedsPaL:** data from **15 countries** has been collected for HIV, TB and HCV medicines with expiry dates and will be supplemented further as data is gathered
- **Source of data:** National regulatory authorities (sometimes aided by patent offices or local experts)

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

SEARCH VIEW

MAP VIEW

Keyword Search



× Darunavir/Cobicistat 800/150 mg

× Ukraine |


Add/Remove Columns ⚙

Export Patent Data ↓

Share This Search ↗

Clear Search ✕

Showing result 1 out of 1

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 Ukraine	Darunavir/Cobicistat 800/150 mg	Cobicistat compound	Granted	UA2008014338	06/07/2027
		Cobicistat compound	Granted	UA200909677	22/02/2028
		Cobicistat tablets	Granted	UA2010014398	01/05/2029
		Cobicistat tablets	Granted	UA2011010569	04/02/2030
		Cobicistat intermediates	Granted	UA2011011540	01/04/2030
		Darunavir compound	Not Filed		

Data Exclusivity:

Test data exclusivity until 15/09/2021

Licence(s):

Bilateral licences on COBI

MPP licence on cobicistat (COBI)



medicines
patent
pool

MAP VIEW - NEW FEATURE

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

SEARCH VIEW

MAP VIEW

Select a product to display related patent or licence information per country directly on the map.

Product

Share This Search

Clear search



HIGHLIGHT COUNTRIES ON THE MAP

- With at least one patent granted/filed
- With at least one compound patent granted/filed
- Included in licence(s)

Select a country to see patent(s)/patent application(s)


MAP VIEW- PATENT INFORMATION

Select a product to display related patent or licence information per country directly on the map.

Glecaprevir/Pibrentasvir 100/40 mg

Share This Search

Clear search



HIGHLIGHT COUNTRIES ON THE MAP

- With at least one patent granted/filed
- With at least one compound patent granted/filed
- Included in licence(s)

Patents

IN1310/DELNP/2013

IN201817002543

IN201817004313

IN201818021052

IN2891/DELNP/2013

[Link to Patent card](#)


MAP VIEW – LICENCE INFORMATION

Select a product to display related patent or licence information per country directly on the map.

Dolutegravir 10 mg

Share This Search

Clear search



HIGHLIGHT COUNTRIES ON THE MAP

- With at least one patent granted/filed
- With at least one compound patent granted/filed
- Included in licence(s)

Licences

MPP licence on paediatric formulations of dolutegravir (DTG)

[Link to Licence card](#)



medicines
patent
pool

UPDATES

HOW IS NATIONAL/REGIONAL PATENT DATA OBTAINED?

- Automatic data feeds from Esp@acenet
- National patent collections on PatentScope
- Patent holder disclosures
 - MPP licences, Pat-INFORMED, disclosures to patent offices
- National /Regional Patent Offices
 - On-line searches, direct communications with patent office, local experts
 - MOUs with patent offices



MOUs WITH NATIONAL/REGIONAL PATENT OFFICES



ARIPO



El Salvador



South Africa



EPO



Chile



Argentina



Ecuador



Brazil



Uruguay



Dominican Republic

The MPP looks forward to expanding its network of collaborating patent offices

MOUs WITH NATIONAL/REGIONAL PATENT OFFICES

- Commitment to collaborate in undertaking a small number of **patent searches on essential medicines** (approximately 30 searches a year per patent office)
- To verify the **legal status** of the patents or patent applications and the **expected expiry date**
- Agreement that information can be included in **MedsPaL** with a disclaimer inviting users to contact the patent office if they need further information on a given patent

The MPP's HIV, TB and hepatitis C activities are fully funded by:





THANK YOU

@MEDSPATENTPOOL

WWW.MEDICINESPATENTPOOL.ORG

WWW.MEDSPAL.ORG

Eburrone@medicinespatentpool.org